STE Stock Overview
Provides infection prevention products and services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
STERIS plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$205.74 |
| 52 Week High | US$248.24 |
| 52 Week Low | US$197.82 |
| Beta | 0.84 |
| 1 Month Change | -1.85% |
| 3 Month Change | -9.33% |
| 1 Year Change | -7.91% |
| 3 Year Change | -12.27% |
| 5 Year Change | 33.48% |
| Change since IPO | 9,875.27% |
Recent News & Updates
STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet
Jan 01
STERIS plc's (NYSE:STE) Popularity With Investors Is Clear
Dec 14Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Nov 18Recent updates
STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet
Jan 01STERIS plc's (NYSE:STE) Popularity With Investors Is Clear
Dec 14Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Nov 18What Does STERIS plc's (NYSE:STE) Share Price Indicate?
Oct 19Is STERIS (NYSE:STE) A Risky Investment?
Oct 01Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Sep 16Earnings Tell The Story For STERIS plc (NYSE:STE)
Sep 13Steris: Q2 Numbers Solidify Buy Thesis
Aug 13STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price
Aug 08When Should You Buy STERIS plc (NYSE:STE)?
Jul 04Is STERIS (NYSE:STE) Using Too Much Debt?
Jun 13Steris: Moving On, Losing Its Teeth
Apr 14STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 31% Above Its Share Price
Mar 29STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet
Mar 07Steris: Strong Healthcare Products Growth Coupled With Weak AST Business
Feb 17STERIS plc's (NYSE:STE) Business Is Trailing The Industry But Its Shares Aren't
Feb 15Steris: Comprehensive Sterilization Portfolios Tailored To Procedure Volumes
Nov 08Steris: Remains On Track For Strong Fiscal '24, Added Upsides From Operating Leverage
Sep 01Steris: Continuing To Grow The Product Lineup
Jun 20Steris falls 10% on Q3 revenue, profit miss, 2023 profit guidance lowered
Feb 09Steris declares $0.47 dividend
Feb 01Steris declares $0.47 dividend
Nov 02Steris: Non-GAAP Valuations Supportive Of Substantial Upside
Sep 04Shareholder Returns
| STE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.8% | 2.0% | -0.5% |
| 1Y | -7.9% | 9.8% | 23.2% |
Return vs Industry: STE underperformed the US Medical Equipment industry which returned 9.8% over the past year.
Return vs Market: STE underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| STE volatility | |
|---|---|
| STE Average Weekly Movement | 2.8% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: STE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: STE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 18,000 | Dan Carestio | www.steris.com |
STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services.
STERIS plc Fundamentals Summary
| STE fundamental statistics | |
|---|---|
| Market cap | US$20.67b |
| Earnings (TTM) | US$591.38m |
| Revenue (TTM) | US$5.33b |
34.3x
P/E Ratio3.8x
P/S RatioIs STE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STE income statement (TTM) | |
|---|---|
| Revenue | US$5.33b |
| Cost of Revenue | US$3.01b |
| Gross Profit | US$2.31b |
| Other Expenses | US$1.72b |
| Earnings | US$591.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.99 |
| Gross Margin | 43.42% |
| Net Profit Margin | 11.10% |
| Debt/Equity Ratio | 33.8% |
How did STE perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 00:34 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
STERIS plc is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |